Changes in HRD “Fingerprints” in Patients with Ovarian Cancer and Their Impact on Clinical Outcomes

Videos
Amina Ahmed, MD
Associate Chief Medical Officer
Division Gynecology, Dept OBGYN
Cancer Center of Rush University Medical Center
Chicago, IL
Paula Anastasia, RN, MN, AOCN
GYN Oncology Clinical Nurse Specialist
UCLA Health
Los Angeles, CA
Amina Ahmed, MD, and Paula Anastasia, RN, MN, AOCN, debate the need for rebiopsy and retesting of molecular biomarkers in patients with HRD-discordant responses. The experts agree that reliability of the HRD “fingerprint” is dependent on the validity of the HRD test used as well as the ability to interpret results from these tests.

Related Items


Subscribe to The Oncology Nurse-APN/PA

To sign up for our newsletter or print publications, enter your contact information below.

I'd like to receive: